New drug ACT500 targets dual liver disease in early trial

NCT ID NCT07589400

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-stage trial is testing a new drug called ACT500 in 24 people who have both fatty liver disease and chronic hepatitis B. The main goal is to check the drug's safety and how the body processes it at different doses. Participants will take ACT500 or a placebo daily, and researchers will monitor for side effects and measure drug levels in the blood.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
ACT500 tablets
What this could lead to
If successful, this could point toward a new treatment option for people with both fatty liver disease and chronic hepatitis B.
What could go wrong
This is an early Phase 1 trial with only 24 participants, so it is primarily testing safety and dosing. It is too early to know if ACT500 will be effective or have significant side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHRONIC HEPATITIS B are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Beijing Friendship Hospital, Capital Medical University

    Beijing, China

  • Ruijin Hospital, Shanghai Jiao Tong University School of Medicine

    Shanghai, China

  • The First Affiliated Hospital of Xinjiang Medical University

    Ürümqi, China

  • Xiamen Hospital of Traditional Chinese Medicine

    Xiamen, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.